IGF1 and sensorineural hearing loss disorder: Insulin-like growth factor-1 (IGF-1) [50] recently emerged as a possible factor for treatment of SNHL because it depletes by the mutation of a corresponding human homozygous gene resulting SNHL, negatively correlated with SDB-related hypoxemia [51], and increased in secretion after three months and six months of CPAP use for SDB patients.